ホーム>>Signaling Pathways>> Membrane Transporter/Ion Channel>> P2X purinergic receptor>>(E/Z)-Sivopixant

(E/Z)-Sivopixant (Synonyms: (E/Z)-S-600918)

カタログ番号GC62560

(E/Z)-Sivopixant ((E/Z)-S-600918) は、4 nM の IC50 を持つ強力な P2X3 受容体アンタゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

(E/Z)-Sivopixant 化学構造

Cas No.: 1640808-39-4

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$453.00
在庫あり
5 mg
$405.00
在庫あり
10 mg
$720.00
在庫あり
25 mg
$1,485.00
在庫あり
50 mg
$2,295.00
在庫あり
100 mg
$3,420.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(E/Z)-Sivopixant (Compound I-127) is a potent P2X3 receptor antagonist with an IC50 of 4 nM. (E/Z)-Sivopixant can be used for respiratory diseases research[1].

ATP receptors are roughly classified into an ion channel type P2X family and a G protein coupled type P2Y family. Seven types of subtypes have been reported in the P2X receptor family, and function as non-selective cation channels by forming homotrimers or heterotrimers with other P2X subtypes. Furthermore, P2X3 that the receptor is expressed in neuroepithelial bodies (NEB) of the lungs, and ATP-induced cough, etc., P2X3 receptors It has been suggested that it is involved in information transmission in the respiratory organs[1].

[1]. Kai, Hiroyuki, et al. Amino-triazine derivatives and pharmaceutical composition containing said derivatives. WO2014200078A1.

レビュー

Review for (E/Z)-Sivopixant

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (E/Z)-Sivopixant

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.